AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04502836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preliminary psychological intervention
Description: psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
Study NCT02950181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
Study NCT01152476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: General anesthesia is maintained witn sevoflurane and remifentanil.
Study NCT01152476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
Study NCT00643318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiosurgery
Description: Central tumors defined as \< 2 cm from carina and \< 2 cm from right and left mainstem bronchus and/or \< 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)
Study NCT00809913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short treatment (ciprofloxacin)
Description: 7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
Study NCT00809913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short treatment (ciprofloxacin)
Description: 7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
Study NCT02654132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Study NCT02654132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Study NCT02654132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT02654132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02654132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03593330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Programme
Description: These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
Study NCT00338949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch
Description: Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
Study NCT00338949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
Study NCT04169997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4927
Description: IMP4297 tablet.The starting dose from 100mg QD
Study NCT04169997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos tablet.The starting dose from 100mg QD
Study NCT00894998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - Cristália
Description: Heparin sodium 5000UI - Cristália
Study NCT00894998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium APP
Description: Heparin Sodium 5.000 USP - APP
Study NCT00501956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradialytic Parenteral Nutrition (IDPN)
Description: compounded IDPN, 3 x/week, 16 weeks intervention
Study NCT05612451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedures
Description: Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
Study NCT05612451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-setting calcium hydroxide
Description: non-setting calcium hydroxide
Study NCT05612451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified triple antibiotic paste
Description: modified triple antibiotic paste
Study NCT01494545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
Study NCT01316965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted prevention program HELP(Hospital Elder Life Program)
Description: * A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~* B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~* C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium.
Study NCT02038998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exer-Rest® TL
Description: Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
Study NCT04634032 — intervention group
Intervention type: GENETIC
Intervention: mRNA expression and SNP analysis
Description: mRNA expression and SNP analysis from samples
Study NCT04634032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Peripheral blood sampling for SNP analysis
Study NCT01857102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Soft contact lens to be worn in a daily wear, daily disposable modality for one week
Study NCT01857102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Soft contact lens to be worn in a daily wear, daily disposable modality for one week
Study NCT01857102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A for Astigmatism
Description: Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
Study NCT01857102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A for Astigmatism
Description: Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
Study NCT03654391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: InnoSlim
Description: Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
Study NCT03654391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
Study NCT04026334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline
Description: -125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
Study NCT00422422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5
Study NCT02346994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melt Test Blend 3.2
Description: Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
Study NCT02346994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn Oil
Description: Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
Study NCT01701505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400uL of Kovacaine Mist
Description: 2 unilateral intranasal sprays of 200uL each.
Study NCT01701505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200uL of Kovacaine Mist
Description: 2 unilateral intranasal sprays of 100uL each.
Study NCT01701505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120uL of Kovacaine Mist
Description: 2 unilateral intranasal sprays of 60uL each.
Study NCT03469999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport Injectable Product
Description: Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
Study NCT00568568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
Study NCT01900899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: At 2, 3, 4, 5, 6 years after booster vaccination.
Study NCT01900899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sampling
Description: At 2, 3, 4, 5, 6 years after booster vaccination.
Study NCT03947502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention in neurobiology of pain
Description: The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
Study NCT02020512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03% Bimatoprost
Description: 0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
Study NCT00586898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: leuprolide and goserelin are gonadotropin-releasing hormone analogues
Study NCT00586898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
Study NCT00586898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: A pure nonsteroidal antiandrogen
Study NCT00586898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone transdermal gel
Description: an androgenic anabolic steroid
Study NCT00586898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen transdermal patch
Description: Estradiol is the primary and most potent estrogen
Study NCT01356329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin, Heparin
Description: Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician.
Study NCT03439462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus combined with mFOLFOX6 + bevacizumab
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamid
Description: 1500mg/m2 or 1000mg/m2 (patients >/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 300mg/m2 or 200mg/m2 (patients >/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients >/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 or 0,5-1g/m2 (patients >/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukovorin
Description: 15mg, po 24 hours after methotrexate it
Study NCT01481272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Colony Stimulating Factor
Description: 5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC>1.0x109/l
Study NCT03567161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cavitron ultrasonic surgical aspirator
Description: Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects .
Study NCT01832909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Diet
Description: Controlled diet with 1.5 oz/d of walnuts.
Study NCT01832909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Controlled diet without walnuts.
Study NCT01084213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment of malaria in pregnancy (IST)
Description: Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
Study NCT01084213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-IPTp
Description: Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
Study NCT00878605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
Study NCT00878605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT01443325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: 1 patch for 12 hours within each 24 hours period
Study NCT00194194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate
Description: moderate behavioral management with RD
Study NCT00194194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting Metablic Rate measurements
Description: intensive behavior management
Study NCT03467334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. breve
Description: Bifidobacterium probiotic strain at 1E+08 cfu/day
Study NCT02038998 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exer-Rest® TL
Description: Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
Study NCT00344032 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT03467334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. breve plus L. fermentum
Description: Probiotic combination at 2E+08 cfu/day
Study NCT03467334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone 20 MG
Description: Standard treatment for infant colic
Study NCT01978678 — intervention group
Intervention type: DRUG
Intervention: Pulmicort
Description: ACQ and FeNO
Study NCT01918878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (EYLEA)
Description: INTARAVITREAL INJECTION OF AFLIBERCEPT
Study NCT03517137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
Study NCT03517137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
Study NCT03517137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
Study NCT03517137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
Study NCT03517137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
Study NCT03517137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)